228 related articles for article (PubMed ID: 33576249)
1. Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
Salem A; Men P; Ramos M; Zhang YJ; Ustyugova A; Lamotte M
J Comp Eff Res; 2021 Apr; 10(6):469-480. PubMed ID: 33576249
[No Abstract] [Full Text] [Related]
2. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
Chirila C; Zheng Q; Davenport E; Kaschinski D; Pfarr E; Hach T; Palencia R
Qual Life Res; 2016 May; 25(5):1199-207. PubMed ID: 26424170
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.
Kohler S; Kaspers S; Salsali A; Zeller C; Woerle HJ
Diabetes Care; 2018 Aug; 41(8):1809-1816. PubMed ID: 29907581
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
Ramos M; Ustyugova A; Hau N; Lamotte M
J Comp Eff Res; 2020 Aug; 9(11):781-794. PubMed ID: 32573253
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Kaku K; Haneda M; Sakamaki H; Yasui A; Murata T; Ustyugova A; Chin R; Hirase T; Shibahara T; Hayashi N; Kansal A; Kaspers S; Okamura T
Clin Ther; 2019 Oct; 41(10):2021-2040.e11. PubMed ID: 31561882
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
J Comp Eff Res; 2022 Jan; 11(1):29-37. PubMed ID: 34841893
[No Abstract] [Full Text] [Related]
8. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.
Tamura H; Kondo Y; Ito K; Hasebe M; Satoh S; Terauchi Y
PLoS One; 2022; 17(2):e0262831. PubMed ID: 35171918
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
Abushanab D; Liew D; Marquina C; Al-Badriyeh D; Ademi Z
Endocr Pract; 2022 Jan; 28(1):16-24. PubMed ID: 34389513
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Nguyen E; Coleman CI; Nair S; Weeda ER
J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes.
Zupa MF; Codario RA; Smith KJ
J Comp Eff Res; 2021 Oct; 10(15):1133-1141. PubMed ID: 34490786
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
Reifsnider OS; Pimple P; Brand S; Bergrath Washington E; Shetty S; Desai NR
Diabetes Obes Metab; 2022 Apr; 24(4):652-661. PubMed ID: 34910356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
